Skip to content
Screener

AnaptysBio, Inc. ANAB Total Liabilities & Equity

Total Liabilities & Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$87.63B-7.4%
Eli Lilly logo
Eli LillyLLY
$142.28B+41.0%
Pfizer logo
PfizerPFE
$207.62B-0.2%
Amgen logo
AmgenAMGN
$95.64B+8.8%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$41.73B+9.2%
Biogen logo
BiogenBIIB
$32.09B+13.3%

Other financials

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%
Free cash flow-$25.9M-142%

Valuation

See full
Market cap$1.62B+145%
Enterprise value$1.37B+117%
P/S+1.6×

Profitability

See full
Operating margin17.6%+9.6pp
Net margin-49.9%-22.6pp
FCF margin1.9%+1.0pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity-0.5×
Current ratio7.6×-0.7×

Where this comes from

Reported directly by AnaptysBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219515
Line itemMarch 31, 2026(unaudited)December 31, 2025
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at March 31, 2026 and December 31, 2025, respectively
Common stock, $0.001 par value, 500,000 shares authorized, 29,031 shares and 28,019 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively2928
Additional paid-in capital838,307809,765
Accumulated other comprehensive loss(146)(24)
Accumulated deficit(825,443)(772,559)
Total stockholders’ equity12,74737,210
Total liabilities and stockholders’ equity$329,684$364,395

Item 1. Consolidated Financial Statements

FAQ

What is AnaptysBio, Inc.'s total liabilities & equity?
AnaptysBio, Inc. (ANAB) reported total liabilities & equity of $329.68M in Q1 2026.
How has AnaptysBio, Inc.'s total liabilities & equity changed year-over-year?
AnaptysBio, Inc.'s total liabilities & equity decreased by 21.9% year-over-year, from $422.05M to $329.68M.
What is the long-term trend for AnaptysBio, Inc.'s total liabilities & equity?
Over 5 years (2020 to 2025), AnaptysBio, Inc.'s total liabilities & equity has grown at a -2.6% compound annual growth rate (CAGR), from $416.55M to $364.4M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about AnaptysBio, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude